Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation
Authors:
- 1 October 2021
- journal article
- letter
- Published by Elsevier in Oral Oncology
- Vol. 121, 105332
Abstract
No abstract availableFunding Information
- National Cancer Institute (P30CA046592)
- NIH
This publication has 14 references indexed in Scilit:
- Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).Journal of Clinical Oncology, 2020
- Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal CancerJournal of Clinical Oncology, 2020
- Detection of Early Human Papillomavirus–Associated Cancers by Liquid BiopsyJCO Precision Oncology, 2019
- Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus–Associated Oropharyngeal Squamous Cell CarcinomaJournal of Clinical Oncology, 2019
- Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trialThe Lancet Oncology, 2019
- Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal CancerClinical Cancer Research, 2019
- Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancerAnnals of Oncology, 2018
- Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 studyThe Lancet Oncology, 2017
- Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancerCancer, 2015
- Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG AnalysisJournal of Clinical Oncology, 2008